Released May 8, 2025, before the open
10-Q filed May 8, 2025, 38 days after period end · 0001785530-25-000014
Q1 2025 · 10-Q
Revenue—
Net Income-$18.09M-$18.09M N/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.40-$0.40 N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$17,991,000N/M
Operating Cash Flow-$18,948,000N/M
Free Cash Flowderived-$18,948,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Net Income | -$18.09M | -$16.19M | -$11.98M | -$15.34M |
| EPS Diluted | -$0.40 | -$0.39 | -$0.34 | -$0.56 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR